Last 7 March, the Philippine Chamber of the Pharmaceutical Industry (PCPI), the major industry group of Filipino-owned pharmaceutical companies, inducted its 2024 Board of Directors and Officers in its first General Assembly for 2024 that featured Director-General Dr. Samuel A. Zacate of the Food and Drug Administration (FDA) and Director-General Ernesto Perez of the Anti-Red Tape Authority (ARTA).
During the event, Director-General Dr. Zacate emphasized his goal of ensuring that FDA policies enable and empower the local pharmaceutical industry:
“We at FDA are committed to supporting PCPI and the local pharmaceutical companies by ensuring that FDA policies are updated to meet the local pharmaceutical industry needs and that industry-related processes are accessible and efficient,” said Zacate.
ARTA Director-General Perez also reiterated his commitment to support local pharmaceutical companies by working closely with the FDA and the Department of Health (DOH) to streamline and expedite processes:
“Our aim is to leverage our collective strengths to pave the way for the rise of a Bagong Pilipinas. We are confident that through our unified efforts with FDA and PCPI, we can continue to empower the Philippine pharmaceutical industry to grow and contribute to the local economy,” said Perez.
PCPI’s newly inducted President Dr. Lloyd Balajadia added, “We at the Philippine Chamber of the Pharmaceutical Industry (PCPI) look forward to working together with FDA and ARTA to achieve our vision of a globally competitive and sustainable Philippine pharmaceutical industry that provides Filipinos with high-quality and affordable medicines.”
The newly inducted officers and board of directors comprise of representatives from Filipino-owned pharmaceutical companies.
